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Developments in the biological sciences in the 
last years have changed mankind's ability to 
manipulate the genetics, cell biology and physiology of 
biological organisms. These techniques, collectively 
termed biotechnology, create the opportunity for 
modifying domestic animals in ways that markedly 
increase the efficiency of production. Among the 
procedures being developed for animal production 
systems are marker-assisted selection of specific alleles of 
a gene that are associated with high production, 
production of transgenic animals, production of large 
amounts of previously-rare proteins through use of 
genetically-engineered bacteria or other cells and 
identification of new biologically-active molecules as 
potential regulators of animals function. 
Transgenic animals are animals in which part of a 
foreign gene (i.e., transgene) is inserted in their genome. 
A typical strategy for producing a transgenic animal is 
illustrated in Fig. 1. The vast majority of transgenic 
animals (mice) have been produced to answer basic 
Biogeneaotor 
research questions. Molecular biologists have used this 
technology to characterise genetic regulatory elements. 
In some systems such as mammary glands that lack good 
cell culture models, transgenic animals are one of the few 
approaches available to researchers to identify which 
genetic sequences confer tissue specificity, 
developmental gene regulation and feedback control of 
gene expression. 
Transgenic technology has been used to perturb 
homeostasis of various systems to study immunology, 
neurology, development, thryroid function, circulatory 
and cardiac function, intermediary metabolism, muscle 
development, bone growth, haemoglobin switching and 
reproduction[ll. 
Transgenic animals have also been used to generate 
a wide array of disease models, such as those for sickle 
cell disease, prostatic hyperplasia, atherosclerosis, 
retinoblastoma, diabetes mellitus, learning impairment and 
cystic fibrosis[31. In all studies mentioned, the mouse 
served as the animal model. For many of these studies a 
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Fig. 1: Typical strategy for producing a transgenic animal. In the study illustrated, the goal is to produce a transgenic 
cow that secretes a pig protein into milk[21 
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larger animal model would be desirable[ll. Examples of 
diseases studied in farm animal models are shown in 
Table 1. 
Table 1: Animal models of human disease[4J 
Animal group Biomedical problem Specific disease 
Cattle Genetic/development defect Chediak-Higashi syndrome 
Hereditary parakeratosis 
Hereditary syndacty ly 
Hereditary thymic 
hypoplasia, zinc deficiency, 
lethal trait A 46 
Hydrocephalus Tibial 
hemimelia 
Lymphosarcoma 
Sheep 
Goat 
Horse 
Pig 
Neoplastic disease 
Metabolic/nutritional disease 
Degenerative disease 
Infectious disease 
Ultimobranchial thyroid 
tumors 
Glycogenosis, Type II 
GMl gangliosidosis 
Mannosidosis, induced 
Mannosidosis, spontaneous 
Osteopetrosis 
Pancreatolithiasis 
Ostertagiasis rotaviral 
enteritis venereal vibriosis 
Genetic/developmental defect Muscular dystrophy 
Dubin-johnson syndrome 
Ilberts syndrome 
Neoplastic disease Adenocarcinoma, intestine 
Lymphosarcoma 
Pulmonary carcinoma 
Metabolic/nutritional disease Congenital goiter 
Copper poisoning, chronic 
Glucose-6-phosphate 
dehydrogenase deficiency 
Glutathione deficiency 
Mannosidosis, induced 
Photosensitivity 
Degenerative disease Prosthetic cardiac valves 
Ceroid-lipofuscinosis 
Anti-BM 
glomerulonephritis 
Infectious disease Bluetongue Jaagziekte 
Hereditary myotonia 
Agammaglobulinemia, X-
linked Anti-GrvIB nephritis 
Combined 
inummodeficiency (severe) 
Exotosis, multiple, 
hereditary 
Infectious anaemia 
Lymphosarcoma 
Mannosidosis, induced 
Selective IgM deficiency 
Thrombocytopenia purpura 
Vitiligo 
ArthritisCerebrospinal 
lipodystrophy GM2 
Gangliosidosis 
Hypervitaminosis A 
Lactational osteoporosis 
Lymphosarcoma 
Malignant hyperthennia 
Melanoma Ochratoxicosis 
Vitiligo von Willebrand's 
disease 
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Table 2: Examples of human protein lll1der development in milk of 
transgenic animals[7] 
Protein 
ex-I-anti-protease inhibitor Inherited ex-I-antitrypsin 
ex-I-antitrypsin 
anti-thrombin III 
collagen 
Factor IX 
Factor VIII 
fibrinogen 
human fertility honnones 
human haemoglobin 
human serum albumin 
lactoferrin 
deficiency 
anti-inflammatory 
sepsis and disseminated 
intravascular coagulation 
resulting from genetic or 
acquired deficiency 
bums, bone fraction, 
urinary incontinence 
haemophilia 
haemophilia 
fibrin glue, bums, 
surgery, localised 
chemo-therapeutic drug 
delivery 
infertility, contraceptive 
vaccines 
blood replacement for 
transfusion 
surgery, bums, shock, 
trauma 
bacterial gastro-intestinal 
infection 
LatPA venous stasis ulcers 
monoclonal antibodies anti-colon cancer 
protein C protein C deficiency, 
adjunct tPA therapy to 
prevent clot foonation 
tissue plasminogen activator heart attacks, deep vein 
thrombosis, puhnonary 
embolism 
Species 
goat 
goat, sheep 
goat 
cow 
sheep, pig 
pig 
pig, sheep 
goat, cow 
pig 
goat, cow 
cow 
goat 
goat 
pig, sheep 
goat 
Another field of transgenic technology, is to support 
the potential value of transgenic animals in livestock 
production systems. Most transgenic livestock projects 
have focused on enhancing growth in swine by over-
expression of grovvth hormone, IGF-I, or estrogen 
receptor[5l. A smaller number of projects have been 
designed to enhance disease resistance in pigs and sheep 
and recently, transgenic sheep with enhanced wool 
production have been produced. 
In the last 6 years a new industry, the transgenic 
animal bioreactor industry, has developed. The goal of 
this industry IS to produce pharmaceuticals and 
nutraceuticals (food with therapeutic value) primarily in 
the milk of farm animals[6l. Examples of some human 
proteins developed in milk of transgenic animals are 
shown in Table 2. 
A number of pharmaceutically active human proteins 
have been successfully produced in the milk of transgenic 
animals at commercially viable levels Table 3. The 
estimated arumal US requirements of some transgenic 
proteins are sho"\iVIl in Table 4. 
W'hich mammal to use? Mammals vary quite differently 
III SIze and several of them have been chosen to 
produce recombinant proteins in their milk. Ruminants, 
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Table 3: A comparison of phannaceutically important human proteins 
expressed in the mammary gland of transgenic animals compared 
with e~ression levels in alternate ~stems[8] 
Biological flll1ctionl Expression World-wide 
Protein clinical utility levels* sales ($US) 
Factor IX Blood clotting factor! 
haemophilia B 
treatment 25 ngmL- 1 
(lOO llgmL- 1, 
only 2% active) $ 25,OOO/g 
IX-I-antitrypsin Neutrophil elastase 
inhibitor/emphysema 7mgmL-1 
(60ngmL-6 
cells day-I) $ 100m 
Interleukin-2 Cancer, AIDS and 
leprosy therapy 430 ng mL-1 
(10 Ilg mL-1 
day-I) $ 20m 
t-PA Thrombolytic agent! 
myocardial infarction 3mgmL-1 
(46O llgmL- 1) $ 230m 
Gmwth Hypopituitary 
honnone dwarl'ism! chronic 
renal insufficiency 11 mgmL-1 
(2OO llgmL- 1) $ 575 m 
Protein C Haemostasis regulator 
I stroke, septic shock 1.0 mgmL-1 
«0.4 Ilg mL-1 
h- 1) $ 960m 
*Expression levels obtained in the mammary gland of transgenic animals. 
Values in brackets are production levels achieved by microbial fennentation 
or mammalian cell culture 
Table 4: 
Item 
F VIllI 
FIX' 
Protein C 
ATIII3 
Estimate annual US requirements and costs of some potential 
bioreactor products[ll 
Estimated quantity Current cost per 
needed kg gram $ 
0.3 
4 
10 
21 
Annualmatktt 
$ x ICY' 
Fibrinogen 
Albumin4 
150 
315x1!Y 
2,900,000 
40,000 
10,000 
7000 
1000 
3.56 
882 
160 
100 
150 
150 
1120 
lBlood coagulation factor 8, 2Blood coagulation factor 9, 3Antithrombin 3, 
4Human serum albumin 
Table 5: The estimated number of transgenic animals needed to satisfY the 
annual US market crable 4) for selected phannaceuticals[ll 
Species F VIllI FIX2 Protein C AT lIP Fibrinogen Albumin4 
Rabbit 54 714 1785 3750 27x1!Y 56x106 
Pig 1 1 25 53 380 80Ox1!Y 
Sheep 1 13 33 70 500 105Ox1!Y 
Goat 1 7 17 35 250 525x1!Y 
Cow 1 1 2 3 17 35x103 
lBlood coagulation factor 8, 2Blood coagulation factor 9, 3Antithrombin 3, 
4Human serum albumin 
namely goat and sheep, appear to be the best candidates 
to produce proteins up to several tons per year[9.10l. The 
pig is considered as a possible living fermentor, although 
milk cannot be collected as easily as from rurninants[lll. 
The rabbit produces up to 200-250mL of milk per day. 
Its milk is particularly rich in protein and a significant 
proportion of milk can be obtained. Transgenic rabbits 
can be easily obtained at a relative low cost. This 
species is also highly prolific and it is therefore a good 
candidate for the production of recombinant proteins 
not exceeding 1 kg per year[ 12l. 
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The cow is probably the only mammalian speCIes 
potentially capable of synthesising 400 tons of human 
albumin, which are needed each year Table 5. 
On first inspection, it seems wrreasonable to think 
that an organisation would consider generating 27,000 
rabbits necessary to produce 150 kg of fibrinogen. The 
labour that is required to maintain and milk those animals 
would be enormous, especially in light of the fact that 17 
cows might be capable of producing all of the fibrinogen 
required to satisfy ClUTent US needs. 
However, the required number of rabbits could be 
produced in 3 to 4 years by using homologous males and 
Artificial Insemination (AI). but 7 to 8 years would be 
needed to produce the 17 cows. The efficiency of 
producing transgenic animals should also be considered. 
From about 40 mouse eggs injected only one transgenic 
mouse was produced. The efficiency from sheep, goats 
and cattle is much lower, requiring approximately 110, 90 
and 1600 eggs injections respectively per transgenic 
animal[ 13l. Furthermore, only 50% of transgenic offspring 
express their transgene. Producing a transgenic sheep or 
goat can easily cost $60,000 and producing a transgenic 
cow or bull can exceed $300,000[14l. 
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